<DOC>
	<DOC>NCT02180464</DOC>
	<brief_summary>Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).</brief_summary>
	<brief_title>A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion Criteria (main): mild to moderate stable chronic plaquetype psoriasis with at least two symmetrical lesions with a treatment area of 20 300 cm² and a TSS of ≥ 6; female volunteers of childbearing potential* must agree to use appropriate and reliable methods of contraception written informed consent obtained. Exclusion Criteria (main): severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis, treatment with any locally acting medications which might counter or influence the trial aim within 2 weeks preceding the treatment phase of the trial and during the trial; treatment with any systemic medications which might counter or influence the trial aim or phototherapy/PUVA within 4 weeks preceding the treatment phase of the trial and during the trial; treatment with vitamin A supplements; treatment with any biologics within 3 months preceding the treatment phase of the trial and during the trial, or in the case of ustekinumab, within 6 months; treatment with any immunosuppressive medication within 6 months preceding the treatment phase of the trial and during the trial; known allergic reactions, irritations or hypersensitivity to the active ingredients contraindications according to summary of product characteristics (SmPC) of the active comparator: pregnancy or nursing;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>psoriasis, topical</keyword>
</DOC>